Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Purpose: Genomic instability is a hallmark of cancer and targeting DNA damage response (DDR) is emerging as a promising therapeutic strategy in different solid tumors. The effectiveness of targeting DDR in colorectal cancer has not been extensively explored. Experimental Design: We challenged 112 cell models recapitulating the genomic landscape of metastatic colorectal cancer with ATM, ATR, CHK1, WEE1, and DNA-PK inhibitors, in parallel with chemotherapeutic agents. We focused then on ATR inhibitors (ATRi) and, to identify putative biomarkers of response and resistance, we analyzed at multiple levels colorectal cancer models highly sensitive or resistant to these drugs. Results: We found that around 30% of colorectal cancers, including those carrying KRAS and BRAF mutations and unresponsive to targeted agents, are sensitive to at least one DDR inhibitor. By investigating potential biomarkers of response to ATRi, we found that ATRi-sensitive cells displayed reduced phospho-RPA32 foci at basal level, while ATRi-resistant cells showed increased RAD51 foci formation in response to replication stress. Lack of ATM and RAD51C expression was associated with ATRi sensitivity. Analysis of mutational signatures and HRDetect score identified a subgroup of ATRi-sensitive models. Organoids derived from patients with metastatic colorectal cancer recapitulated findings obtained in cell lines. Conclusions: In conclusion, a subset of colorectal cancers refractory to current therapies could benefit from inhibitors of DDR pathways and replication stress. A composite biomarker involving phospho-RPA32 and RAD51 foci, lack of ATM and RAD51C expression, as well as analysis of mutational signatures could be used to identify colorectal cancers likely to respond to ATRi.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences
Soneson, C., Love, M. I., & Robinson, M. D. (2015) · F1000Research · doi:10.12688/f1000research.7563.1 · Cited by 3,929
The repertoire of mutational signatures in human cancer
Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., Tian Ng, A. W., Wu, Y., Boot, A., Covington, K. R., Gordenin, D. A., Bergstrom, E. N., et al. (2020) · Nature · doi:10.1038/s41586-020-1943-3 · Cited by 3,496
Self-citationPembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S., & Pommier, Y. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2523 · Cited by 1,623
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Pan-cancer whole-genome analyses of metastatic solid tumours
Priestley, P., Baber, J., Lolkema, M. P., Steeghs, N., de Bruijn, E., Shale, C., Duyvesteyn, K., Haidari, S., van Hoeck, A., Onstenk, W., et al. (2019) · Nature · doi:10.1038/s41586-019-1689-y · Cited by 1,106
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., Boyault, S., Sieuwerts, A. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4292 · Cited by 1,086 · cited 1×
“The HRDetect model suitable for mutational signature analysis carried out with samples without matched normal using tumor variants and CNA calls filtered with the pipeline described above was derived on the same training and validation dataset of the original model (37).”
Self-citationRegulation of p53 in response to DNA damage
Lakin, N. D., & Jackson, S. P. (1999) · Oncogene · doi:10.1038/sj.onc.1203015 · Cited by 987 · cited 1×
“We then evaluated TP53, a tumor suppressor gene involved in the cell-cycle control and DDR activation (51).”
Cited by
High-resolution functional mapping of RAD51C by saturation genome editing
Olvera-León, R., Zhang, F., Offord, V., Zhao, Y., Tan, H. K., Gupta, P., Pal, T., Robles-Espinoza, C. D., Arriaga-González, F. G., Matsuyama, L. S. A. S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.039 · Cited by 44
Sogari, A., Rovera, E., Grasso, G., Mariella, E., Reilly, N. M., Lamba, S., Mauri, G., Durinikova, E., Vitiello, P. P., Lorenzato, A., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101376 · Cited by 17
Self-citationDemuth, P., Thibol, L., Lemsch, A., Potlitz, F., Schulig, L., Grathwol, C., Manolikakes, G., Schade, D., Roukos, V., Link, A., et al. (2024) · Cancers · doi:10.3390/cancers16203441 · Cited by 14
“In support of this view, a very recent study provided evidence that PARP inhibition, rather than PARP trapping, is sufficient for killing cancer cells with HRD [73].”
Background
Metadata
- Authors
- Durinikova, E., Reilly, N. M., Buzo, K., Mariella, E., Chilà, R., Lorenzato, A., Dias, J. M. L., Grasso, G., Pisati, F., Lamba, S., Corti, G., Degasperi, A., Cancelliere, C., Mauri, G., Andrei, P., Linnebacher, M., Marsoni, S., Siena, S., Sartore-Bianchi, A., Nik-Zainal, S., Di Nicolantonio, F., Bardelli, A., & Arena, S.
- Venue
- Clinical Cancer Research
- Published
- 2022-07-26
- Volume
- 28
- Issue
- 17
- Pages
- 3874-3889
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W4288042084
- Cited by
- 59
- References
- 18
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-22-0875
- The paper
- Durinikova, E., Reilly, N. M., Buzo, K., Mariella, E., Chilà, R., Lorenzato, A., Dias, J. M. L., Grasso, G., Pisati, F., Lamba, S., Corti, G., Degasperi, A., Cancelliere, C., Mauri, G., Andrei, P., Linnebacher, M., Marsoni, S., Siena, S., Sartore-Bianchi, A., . . . Arena, S. (2022). Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-22-0875
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.